A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung

Abstract

The aim was to investigate the clinicopathological characteristics, diagnosis, and prognosis of sarcomatoid carcinoma of the lung. We reviewed 114 cases of sarcomatoid carcinoma of the lung in patients that were admitted to the First Affiliated Hospital of Zhengzhou University and Anyang Tumor Hospital from January 2009 to March 2018. We analyzed the clinical characteristics, immunohistochemical profiles, treatments, and overall survival of the patients. The patient population included 88 men and 26 women. Median patient age was 65 years (range 37-88 years), and the gender ratio (M/F) was 3.4:1. Median survival was 3.5 months (range 0.5-60 months). Univariate analysis showed that tumor location, tumor size, M stage, TNM stage, chemotherapy, and surgery were all prognostic factors for survival (P < 0.05). We found that T stage, surgery, and chemotherapy were independent prognostic factors for sarcomatoid carcinoma (P < 0.05). Pulmonary sarcomatoid carcinoma is a rare tumor with a poor prognosis. Patients with smaller T stage, complete resection, and chemotherapy exhibited a better prognosis. Early diagnosis and early treatment are important to improve the prognosis of these patients.

Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma

“…Surgery remains the primary treatment approach for PSC, and surgery was performed in most of our patients (91.2%). In line with previous reports (20,21), our study verified the prolongation of survival with surgical treatment compared with nonsurgical treatment (MST, 23.0 vs. 11.0 months, P=0.016). In terms of adjuvant therapy, however, our study found no survival benefit from adjuvant therapy after surgical resection.…”

“…Compared with the other studies (6,(18)(19)(20), our study reported a relatively lower rate of metastatic disease (6.5%) at the initial diagnosis, which may be due to the fact that some metastatic patients were identified in district hospitals were not referred to our hospital. The total cohort had an MST of 22.0 months; however, prior published series reported a relatively short MST ranging from 3.5 to 19.1 months (5,6,(18)(19)(20)(21)(22)(23). This may be largely due to the higher proportions of early-stage and surgically resected patients in our cohort.…”

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

“…3 Patients with pN0 disease had a high rate of vascular invasion (57.1%), indicating that distant metastases may often occur in the early stage; this phenomenon might explain why N stage does not affect prognosis. 12,23,28,29 The presenting complications of PSC are similar to those of other lung cancers. In addition, tumor metastasis often includes various involved organs, such as the lung, adrenal glands, pleura, brain, bone, or liver, but may also include unusual anatomic sites, such as subdiaphragmatic nodes, kidney, peritoneum, pancreas, skin, and right ventricle.…”

“…Palliative anti-tumor therapy is often the best choice to prolong OS. 12 Drug resistance can occur with platinum plus pemetrexed chemotherapy in a short time, resulting in tumor recurrence. 52 The efficacy of combined adriamycin and ifosfamide chemotherapy to treat patients with metastatic PSC has been limited.…”

“… 28 In Hou et al .’s investigation, for 45 of 114 patients receiving neoadjuvant or adjuvant chemotherapy, the survival rate was significantly improved compared with patients who did not receive neoadjuvant chemotherapy. 12 Due to the small number of patients and individual differences, these data do not fully prove that neoadjuvant chemotherapy is ineffective.…”